Prostate Cancer - Results from #23840

Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: Identification of risk categories according to number of positive nodes and Gleason score - Abstract February 18, 2013

Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy - Abstract February 18, 2013

Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer - Abstract February 18, 2013

GU Cancers Symposium 2013 - Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor, by Howard I. Scher, MD - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - Updated interim analysis of COU-AA-302, a randomized phase III study of abiraterone acetate in patients with metastatic castration-resistant prostate cancer without prior chemotherapy, by D. E. Rathkopf, MD - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up, Andrew Loblaw, MD, FRCPC, MSc - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study, by Abdenour Nabid, et al. - Session Highlights February 16, 2013

GU Cancers Symposium 2013 - Novel strategies for targeting the androgen-receptor axis: PARP1 as a mediator of androgen receptor-dependent transcriptional control, by Karen E. Knudsen, PhD - Session Highlights February 15, 2013

The changing landscape in the treatment of metastatic castration-resistant prostate cancer - Abstract February 15, 2013

Diffusion-weighted magnetic resonance imaging for the evaluation of prostate cancer: Optimal b value at 3T - Abstract February 15, 2013

Extended salvage pelvic and retroperitoneal lymph node dissection due to prostate cancer relapse - Abstract February 15, 2013

GU Cancers Symposium 2013 - Clinical trial design strategies in the post-abiraterone/enzalutamide setting, by Charles J. Ryan, MD, UCSF - Session Highlights February 15, 2013

Development and evaluation of an actuated MRI-compatible robotic system for MRI-guided prostate intervention - Abstract February 15, 2013

Primary care physicians' use of an informed decision-making process for prostate cancer screening - Abstract February 15, 2013

Androgen deprivation therapy toxicity and management for men receiving radiation therapy - Abstract February 15, 2013

Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy - Abstract February 15, 2013

GU Cancers Symposium 2013 - What tools are available to aid in the use of active surveillance? The imaging perspective - Session Highlights February 15, 2013

GU Cancers Symposium 2013 - High-risk prostate cancer treated with pelvic radiotherapy and 36 vs 18 months of androgen blockade: Results of a phase III randomized trial - Slide Presentation February 15, 2013

Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer - Abstract February 15, 2013

GU Cancers Symposium 2013 - Updated analysis of radium-223 dichloride impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 randomized trial (ALSYMPCA) - Poster February 15, 2013

Page 1193 of 1436